Illumina, Inc. (ILMN) Stake Raised by Strs Ohio
Strs Ohio raised its position in Illumina, Inc. (NASDAQ:ILMN) by 256.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 132,313 shares of the life sciences company’s stock after buying an additional 95,208 shares during the period. Strs Ohio owned 0.09% of Illumina worth $22,958,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Advocacy Wealth Management Services LLC bought a new stake in Illumina during the first quarter valued at about $102,000. Advisory Services Network LLC bought a new stake in Illumina during the first quarter valued at about $117,000. Gemmer Asset Management LLC boosted its stake in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares in the last quarter. Patten Group Inc. boosted its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. boosted its stake in shares of Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares in the last quarter. 93.81% of the stock is currently owned by institutional investors.
Shares of Illumina, Inc. (NASDAQ ILMN) traded down 0.21% during mid-day trading on Friday, hitting $194.25. The company’s stock had a trading volume of 695,985 shares. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $199.95. The company has a market cap of $28.36 billion, a PE ratio of 38.97 and a beta of 0.83. The stock has a 50-day moving average of $179.63 and a 200-day moving average of $173.73.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The business had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. Illumina’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.86 earnings per share. On average, equities research analysts forecast that Illumina, Inc. will post $3.65 EPS for the current year.
Several equities research analysts recently weighed in on ILMN shares. Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target on the stock. in a research report on Wednesday, May 31st. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 price objective for the company in a research note on Thursday, July 27th. Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $170.00 to $215.00 in a research note on Monday, August 7th. First Analysis raised shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a research note on Wednesday, August 2nd. Finally, Barclays PLC reissued an “equal weight” rating and set a $150.00 target price on shares of Illumina in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $177.01.
In related news, Director Frances Arnold sold 825 shares of Illumina stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $174.77, for a total transaction of $144,185.25. Following the completion of the sale, the director now owns 8,816 shares of the company’s stock, valued at $1,540,772.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $175.53, for a total value of $2,632,950.00. Following the sale, the director now directly owns 534,176 shares of the company’s stock, valued at approximately $93,763,913.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 134,010 shares of company stock valued at $23,946,015. 1.60% of the stock is currently owned by insiders.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.